Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

SOP for controlled copies for Contract Manufacturing, CRO and Global Outsourcing Models

Posted on By


SOP for controlled copies for Contract Manufacturing, CRO and Global Outsourcing Models

SOP for controlled copies for Contract Manufacturing, CRO and Global Outsourcing Models

1. Introduction

The purpose of this Standard Operating Procedure (SOP) is to outline the requirements and processes for managing controlled copies of documents within the frameworks of Contract Manufacturing, Contract Research Organizations (CROs), and Global Outsourcing Models. Accurate management of controlled copies is essential for maintaining compliance with regulatory standards including FDA, EMA, and MHRA, particularly in the context of Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP).

This document will serve as a comprehensive guide for professionals in regulatory affairs, quality assurance (QA), and clinical operations. It ensures that all phases from document creation to revision and use are compliant with applicable regulations and internal quality management systems.

See also  SOP for controlled copies Checklists for Audit-Ready Documentation and QA Oversight

2. Scope

This SOP applies to all departments involved in the generation, approval, issuance, and management of controlled copies of documents, including but not limited to:

  • Quality Assurance
  • Manufacturing
  • Clinical Operations
  • Regulatory Affairs

The SOP covers processes for controlled copies of Standard Operating Procedures (SOPs), batch records, validation protocols, clinical study documents, and any other pertinent materials requiring controlled handling.

3. Definitions

Understanding key terms is critical for the effective application of this SOP:

  • Controlled Copy: A version of a document that is distributed under strict conditions to ensure its integrity and usage compliance.
  • Source Document: Original documents from which data is derived.
  • Document Control: A system for managing documents ensuring they are accurate, available, and current.
  • Data Integrity: The accuracy and completeness of data throughout its lifecycle.

4. Responsibilities

The successful implementation of this SOP requires defined responsibilities:

  • Quality Assurance (QA): Ensures compliance with this SOP through regular audits and reviews.
  • Document Control Administrator: Manages and maintains the master document list, distribution of controlled copies, and ensures timely updates.
  • Department Heads: Accountable for ensuring their teams understand and adhere to this SOP.

5. Procedure for Managing Controlled Copies

This section provides a step-by-step process for managing controlled copies effectively:

5.1 Document Creation

All documents requiring controlled copy status must follow the organization’s document creation protocols:

  • Draft the document using the standardized template and include all required fields.
  • Designate the authors and stakeholders for review.
See also  SOP for controlled copies: GMP Compliance and Regulatory Expectations in US, UK and EU

5.2 Review and Approval

Once the document draft is completed, the following steps must be taken for review and approval:

  • Circulate the draft to the designated reviewers.
  • Compile feedback and make necessary revisions.
  • Submit the final draft for formal approval by authorized personnel.

5.3 Issuance of Controlled Copies

After approval, the document control administrator is responsible for issuing controlled copies:

  • Generate the controlled copy list and number each copy issued.
  • Ensure that recipients acknowledge receipt through a formal document tracking system.

5.4 Maintenance and Revision

Controlled documents require ongoing maintenance:

  • Regularly review documents at defined intervals or upon request of stakeholders.
  • Implement a change management process to modify documents.

Upon revision, a new version number must replace the old version, and the former copies must be retrieved to prevent usage of outdated versions.

5.5 Tracking and Archiving

Documentation must be effectively tracked throughout its lifecycle:

  • Utilize a Document Management System (DMS) or other tools for tracking the location and status of controlled copies.
  • Archive outdated documents securely to maintain data integrity and compliance with regulatory obligations.

6. Compliance and Regulatory Considerations

Controlled copies must adhere to stringent compliance requirements. Professionals must be aware of relevant guidelines and principles:

  • GMP compliance as stipulated by the FDA, EMA, and MHRA mandates adherence to strict document management practices.
  • Compliance with 21 CFR Part 11 and Annex 11 ensures electronic records and signatures are managed appropriately.
  • Regular audits should be conducted to ensure ongoing compliance and readiness for potential inspections.
See also  Step-by-Step SOP for controlled copies Implementation Guide for GMP Manufacturing Sites

7. Documentation and Record Keeping

Consistent record-keeping is essential for demonstrating compliance and supporting inspection readiness:

  • Maintain a master list of all current controlled documents, including version history and the distribution list.
  • Document any deviations from this SOP and their resolutions in a corrective actions log.
  • Securely store all records as required by regulatory bodies to support audits and other inquiries.

8. Training and Communication

Effective communication and training are pivotal in the SOP implementation process:

  • Conduct training sessions for all relevant staff on controlled copy management processes outlined in this SOP.
  • Implement refresher training upon any updates to the SOP or changes in compliance requirements.
  • Encourage open communication to address questions or clarifications about the process.

9. Conclusion

The management of controlled copies within Contract Manufacturing, CROs, and Global Outsourcing Models is vital for ensuring compliance and quality in pharmaceutical operations. Following this SOP will contribute to maintaining comprehensive control over document integrity, thereby facilitating compliance with GMP, GCP, and other regulatory requirements. By establishing a robust controlled copy management process, organizations can enhance their inspection readiness in light of FDA, EMA, and MHRA inspections.

10. References

For further information and guidelines concerning controlled copy management, refer to official resources from FDA, EMA, and the MHRA.

SOP for controlled copies Tags:Data Integrity, EMA, FDA, GMP compliance, MHRA, Part 11, QA, regulatory affairs, SOP

Post navigation

Previous Post: Common Errors in SOP for controlled copies Cited in Regulatory Inspections and How to Fix Them
Next Post: Digital SOP for controlled copies in eQMS, LIMS and MES Systems: Best Practices

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version